EFFICACY OF HPV VACCINE IN PREVENTING CERVICAL CANCER AND OTHER MALIGNANCIES
Sažetak
Infekcija humanim papiloma virusom (HPV) je jedna od najrasprostranjenijih polno prenosivih infekcija širom sveta, odgovorna za značajan broj obolelih i umrlih godišnje. Predstavlja jedan od faktora rizika za nastanak raka grlića materice, raka usne duplje i ždrela, raka vagine, raka vulve, raka penisa i raka anusa, a uzrokuje i nastanak genitalnih bradavica. Uvođenjem licenciranih globalno priznatih profilaktičkih HPV vakcina (npr. Cervarix, Gardasil, Gardasil 9, Cecolin, Walrinvax i Cervavac), baziranih na česticama sličnim virusu (engl. Virus-Like Particles), napravljenih od proteinskih komponenti virusa, ali bez genetskog materijala virusa, je doprinelo značajnom smanjivanju broja obolelih od raka grlića materice posebno u visoko razvijenim zemljama, gde se koristi i skrining test (Pap test). Uprkos uvođenju i implementaciji ovih vakcina, maligniteti povezani sa HPV-om i dalje predstavljaju globalni problem. Cilj ovog preglednog rada je da analizira efikasnost HPV vakcine u prevenciji raka grlića materice i drugih malignih tumora.
Reference
Jones HW Jr. Record of the first physician to see Henrietta Lacks at the Johns Hopkins Hospital: history of the beginning of the HeLa cell line. Am J Obstet Gynecol 1997; 176(6):S227-8. doi: 10.1016/s0002-9378(97)70379-x.
zur Hausen H. Papillomaviruses and cancer: from basic studies to clinical application. Nat Rev Cancer 2002;2(5):342-50. doi: 10.1038/nrc798.
Frazer IH. The HPV Vaccine Story. ACS Pharmacol Transl Sci 2019;2(3):210-212. doi: 10.1021/acsptsci.9b00032
Illah O, Olaitan A. Updates on HPV Vaccination. Diagnostics (Basel) 2023;13(2):243. doi: 10.3390/diagnostics13020243. ;
World Health Organization. Global market study HPV. March 2022. Available online: https://cdn.who.int/media/docs/default-source/immunization/mi4a/who-mi4a-global-market-study-hpv.pdf?sfvrsn=649561b3_1&download=true
Human papillomavirus vaccines: WHO position paper. Wekly Epidemiol Rec 1992; (19):241–68. Available at: https:// iris.who.int/bitstream/handle/10665/365350/ WER9750engfre.pdf?sequence= 1&isAllowed=y )
The Lancet Oncology. HPV vaccination in south Asia: new progress, old challenges. Lancet Oncol 2022; 23(10):1233. doi:10.1016/S1470-2045(22)00567-8
Mlynarczyk-Bonikowska B, Rudnicka L. HPV Infections-Classification, Pathogenesis, and Potential New Therapies. Int J Mol Sci 2024; 25(14):7616. doi: 10.3390/ijms25147616.
McBride AA. Human malignancies associated with persistent HPV infection. Oncologist 2024; 29(6):457-464. doi: 10.1093/oncolo/oyae071.
Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public Health 2023; 16(4):626-631. doi: 10.1016/j.jiph.2023.02.014
McBride AA. Human malignancies associated with persistent HPV infection. Oncologist 2024; 29(6):457-464. doi: 10.1093/oncolo/oyae071
Doorbar J. The human Papillomavirus twilight zone - Latency, immune control and subclinical infection. Tumour Virus Res 2023; 16:200268. doi: 10.1016/j.tvr.2023.200268.
Egawa N. Papillomaviruses and cancer: commonalities and differences in HPV carcinogenesis at different sites of the body. Int J Clin Oncol 2023; 28(8):956-964. doi: 10.1007/s10147-023-02340-y
Global Cancer Observatory. Statistics at a glance, 2022. In Global Cancer Observatory: Cancer Today [Report]. International Agency for Research on Cancer, 2024. Available at: https://gco.iarc.who.int/media/globocan/factsheets/populations/900-world-fact-sheet.pdf
Oyouni AAA. Human papillomavirus in cancer: Infection, disease transmission, and progress in vaccines. J Infect Public Health 2023; 16(4):626-631. doi: 10.1016/j.jiph.2023.02.014
de Martel C, Plummer M, Vignat J, Franceschi S. Worldwide burden of cancer attributable to HPV by site, country and HPV type. Int J Cancer 2017;141(4):664-670. doi: 10.1002/ijc.30716
Singh D, Vignat J, Lorenzoni V, Eslahi M, Ginsburg O, Lauby-Secretan B, et al. Global estimates of incidence and mortality of cervical cancer in 2020: a baseline analysis of the WHO Global Cervical Cancer Elimination Initiative. Lancet Glob Health 2023; 11(2):e197-e206. doi: 10.1016/S2214-109X(22)00501-0
Branda F, Pavia G, Ciccozzi A, Quirino A, Marascio N, Gigliotti S, et al. Human Papillomavirus (HPV) Vaccination: Progress, Challenges, and Future Directions in Global Immunization Strategies. Vaccines (Basel) 2024;12(11):1293. doi: 10.3390/vaccines12111293
Lien AC, Johnson GS, Guan T, Burns CP, Parker JM, Dong L, et al. The Past, Present, and Future of Cervical Cancer Vaccines. Vaccines (Basel) 2025; 13(2):201. doi: 10.3390/vaccines13020201
Cheng L, Wang Y, Du J. Human Papillomavirus Vaccines: An Updated Review. Vaccines (Basel) 2020; 8(3):391. doi: 10.3390/vaccines8030391
Wang R, Huang H, Yu C, Li X, Wang Y, Xie L. Current status and future directions for the development of human papillomavirus vaccines. Front Immunol 2024;1 5:1362770. doi: 10.3389/fimmu.2024.1362770
HPV dashboard. (n.d.). Available at: https://www.who.int/teams/immunization-vaccines-and-biologicals/diseases/human-papillomavirus-vaccines-%28HPV%29/hpv-clearing-house/hpv-dashboard
Kovačević G, Božić Nedeljković B, Patić A, Radovanov J, Hrnjaković-Cvjetković I. Human papillomavirus-specific antibody status among unvaccinated subjects in the region of Vojvodina, Serbia. Cent Eur J Public Health 2023; 31(1):57-62. doi: 10.21101/cejph.a7257
Vaccine Scheduler ECDC. (n.d.). Available at: https://vaccine-schedule.ecdc.europa.eu/Scheduler/ByDisease?SelectedDiseaseId=38&SelectedCountryIdBy
Immunize.org. HPV vaccine requirements for elementary and secondary schools. (2024, October 25). Available at: https://www.immunize.org/official-guidance/state-policies/vaccine-requirements/hpv-secondary-2024/
Regional Immunisation Technical Advisory Group (RITAG), WHO Regional Office for Africa (AFRO), UHC/UCN Cluster, World Health Organization, & WHO African Region. (2023). Regional Immunisation Technical Advisory Group (RITAG) MEETING REPORT. Available at: https://www.afro.who.int/sites/default/files/2024-05/RITAG%20MEETING%20REPORT_16052024.pdf
Tse KY, Tan AL, Subedi K, Pervin S, Gupta K, Tjokroprawiro BA, et al. The AOFOG recommendations on human papillomavirus vaccination in the Asia-Pacific region. J Obstet Gynaecol Res 2024; 50(S1):95–102. Available at: https://doi.org/10.1111/jog.16034
Rancic NK, Miljkovic PM, Deljanin ZM, Marinkov-Zivkovic EM, Stamenkovic BN, Bojanovic MR, et al. Knowledge about HPV Infection and the HPV Vaccine among Parents in Southeastern Serbia. Medicina (Kaunas). 2022; 58(12):1697. doi: 10.3390/medicina58121697
Štrbac M, Joksimović M, Vuković V, Ristić M, Lončarević G, Kanazir M, et al. Overview of the Implementation of the First Year of Immunization against Human Papillomavirus across Different Administrative Units in Serbia and Montenegro. Vaccines (Basel) 2024; 12(7):803. doi: 10.3390/vaccines12070803
Institute of Public Health of Serbia “Dr Milan Jovanović Batut,” Jovanović V, Miljus D, Živković Perišić S, Božić Z, & CanReg 4 – Descriptive Epidemiology, Internacional Agency for Research on Cancer, WHO, 2005. (2022). MALIGNANT TUMOURS IN REPUBLIC OF SERBIA (T. Gruden, Interviewer; D. Miljus, S. Zivkovic Perisic, & Z. Bozic, Eds.; S. Paunovic, Trans.). Institute of Public Health of Serbia “Dr Milan Jovanović Batut.” Available at: https://www.batut.org.rs